Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...

With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia ...

而在不同AD小鼠模型中，他们也证实了，使用坏死性凋亡抑制剂（如ponatinib和dabrafenib）阻断坏死性凋亡过程不仅可以挽救神经元的死亡，还能在某种 ...

The study population was heavily pretreated: approximately 18% of patients had received two prior TKIs, 28% three, and 54% at least four. Forty-six patients (57.5%) had received ponatinib; 25 (31.3%), ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Forty-six patients (57.5%) had received ponatinib; 25 (31.3%), asciminib; and 11 (13.8%), both medications. 1 Among all evaluable patients with chronic-phase CML (CP-CML), the complete cytogenetic ...

The study population was heavily pretreated: approximately 18% of patients had received two prior TKIs, 28% three, and 54% at least four. Forty-six patients (57.5%) had received ponatinib; 25 (31.3%), ...